Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many
metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low …

Vaccines have had a profound impact on the management and prevention of infectious
disease. In addition, the development of vaccines against chronic diseases has attracted …

Folate receptor α (FRα) came into focus as an anticancer target many decades after the
successful development of drugs targeting intracellular folate metabolism, such as …

The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

Breast carcinomas repeat their number and grow exponentially making it extremely frequent
malignancy among women. Approximately, 70–80% of early diagnosed or non-metastatic …

Triple negative breast cancer (TNBC) is a subtype of breast cancer characterized by
absence of estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal …

This review discusses peptide epitopes used as antigens in the development of vaccines in
clinical trials as well as future vaccine candidates. It covers peptides used in potential …

In ovarian cancer (OC), IL-17-producing T cells (Th17s) predict improved survival, whereas
regulatory T cells predict poorer survival. We previously developed a vaccine whereby …

Cancer represents a serious concern for human life and health. Due to drug resistance and
the easy metastasis of tumors, there is urgent need to develop new cancer treatment …